CVS HEALTH Corp

CVSSEC EDGAR

Retail-Drug Stores and Proprietary Stores(DE)CIK: 64803

Concept	FY2025	FY2024	FY2023	FY2022	FY2021
Revenue from Contract with Customer, Excluding Assessed Tax	—	—	—	—	—
Cost of Goods and Services Sold	$217.1B	$196.9B	$175.8B	$164.0B	$158.7B
Gross Profit	—	—	—	—	—
Operating Expenses	—	—	—	—	—
Operating Income (Loss)	$13.7B	$8.0B	$13.3B	$13.9B	$12.0B
Interest Expense	—	—	$2.5B	$2.9B	$3.0B
Other Nonoperating Income (Expense)	$88.0M	$169.0M	$182.0M	$206.0M	$124.0M
Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest	$11.2B	$5.8B	$10.5B	$9.8B	$9.0B
Income Tax Expense (Benefit)

Concept	FY2025	FY2024	FY2023	FY2022	FY2021
Assets	$253.2B	$249.7B	$228.3B	$233.0B	$230.7B
Assets, Current	$68.6B	$67.9B	$65.6B	$60.0B	$56.4B
Cash and Cash Equivalents, at Carrying Value	$8.2B	$12.9B	$9.4B	$7.9B	$5.7B
Accounts Receivable, after Allowance for Credit Loss, Current	$36.5B	$35.2B	$27.3B	$24.4B	$21.7B
Inventory, Net	$18.1B	$18.0B	$19.1B	$17.8B	$18.5B
Liabilities	$177.5B	$173.1B	$156.5B	$157.6B	$161.0B
Liabilities, Current	$84.6B	$79.2B	$69.4B	$67.8B

Concept	FY2025	FY2024	FY2023	FY2022	FY2021
Net Cash Provided by (Used in) Operating Activities	$13.4B	$16.2B	$18.3B	$15.9B	$12.8B
Net Cash Provided by (Used in) Investing Activities	-$20.9B	-$5.0B	-$5.3B	-$5.5B	-$3.3B
Net Cash Provided by (Used in) Financing Activities	$2.7B	-$10.5B	-$11.4B	-$7.7B	-$7.7B
Payments to Acquire Property, Plant, and Equipment	$3.0B	$2.7B	$2.5B	$2.4B	$2.5B
Payments of Dividends	$3.1B	$2.9B	$2.6B	$2.6B	$2.6B
Payments for Repurchase of Common Stock	$2.0B	$3.5B	$0.00	$0.00	—

Access SEC EDGAR data via REST API. Free tier available.

from sec_edgar import SecEdgar

api = SecEdgar("YOUR_KEY")
api.revenue("AAPL", limit=5)